[go: up one dir, main page]

CA2313805A1 - Procede pour reduire la sensibilite a l'infection a vih - Google Patents

Procede pour reduire la sensibilite a l'infection a vih Download PDF

Info

Publication number
CA2313805A1
CA2313805A1 CA002313805A CA2313805A CA2313805A1 CA 2313805 A1 CA2313805 A1 CA 2313805A1 CA 002313805 A CA002313805 A CA 002313805A CA 2313805 A CA2313805 A CA 2313805A CA 2313805 A1 CA2313805 A1 CA 2313805A1
Authority
CA
Canada
Prior art keywords
cells
cd40l
cell
hiv
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002313805A
Other languages
English (en)
Inventor
Elaine K. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2313805A1 publication Critical patent/CA2313805A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé pour diminuer la sensibilité des cellules à l'infection par un rétrovirus. Le procédé consiste à mettre les cellules au contact d'une protéine de liaison au CD40 utilisée en quantité suffisante pour réduire l'expression du récepteur CCR5 de la chémokine, et/ou à inhiber la réplication du rétrovirus après son entrée. Ce procédé convient pour le traitement d'individus infectés ou risquant d'être infectés par le VIH. Les protéines de liaison au CD40 incluent le ligand CD40, des anticorps monoclonaux qui se lient spécifiquement au CD40, ou des combinaisons desdits éléments. Les protéines de liaison au CD40 peuvent également s'utiliser en association avec d'autres cytokines, y compris GM-CSF, IL-2 et IL-15.
CA002313805A 1997-12-19 1998-12-18 Procede pour reduire la sensibilite a l'infection a vih Abandoned CA2313805A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6835597P 1997-12-19 1997-12-19
US60/068,355 1997-12-19
US9847498P 1998-08-31 1998-08-31
US60/098,474 1998-08-31
PCT/US1998/027005 WO1999032138A1 (fr) 1997-12-19 1998-12-18 Procede pour reduire la sensibilite a l'infection a vih

Publications (1)

Publication Number Publication Date
CA2313805A1 true CA2313805A1 (fr) 1999-07-01

Family

ID=26748884

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002313805A Abandoned CA2313805A1 (fr) 1997-12-19 1998-12-18 Procede pour reduire la sensibilite a l'infection a vih

Country Status (6)

Country Link
EP (1) EP1059932A1 (fr)
JP (1) JP2001526241A (fr)
AU (1) AU2004199A (fr)
CA (1) CA2313805A1 (fr)
IL (1) IL136731A0 (fr)
WO (1) WO1999032138A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
AU2002232447A1 (en) * 2000-11-02 2002-05-15 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7175838B2 (en) 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
JP2008507255A (ja) 2004-03-12 2008-03-13 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
EP1768662A2 (fr) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
AU2006202318A1 (en) 2005-06-02 2006-12-21 Wing-Yee Chan The preparation of multipotent stem cells and the use thereof
EP2066339B1 (fr) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour améliorer des réponses immunes
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
WO2009059298A2 (fr) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions et procédés pour amplifier des réponses immunitaires à l'eimeria
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
ES2753142T3 (es) 2010-06-09 2020-04-07 Univ Arkansas Vacuna y métodos para reducir una infección por Campylobacter
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (fr) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions et procédés pour améliorer les réactions immunitaires aux pathogènes entériques
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
CA2179196A1 (fr) * 1993-12-23 1995-06-29 Richard J. Armitage Procede de prevention ou de traitement de maladies caracterisees par des cellules neoplasiques exprimant le cd40
DK0812206T3 (da) * 1995-03-01 2002-09-09 Immunex Corp Fremgangsmåde til stimulering af en immunrespons

Also Published As

Publication number Publication date
IL136731A0 (en) 2001-06-14
JP2001526241A (ja) 2001-12-18
WO1999032138A1 (fr) 1999-07-01
EP1059932A1 (fr) 2000-12-20
AU2004199A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
Hochrein et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells
CA2313805A1 (fr) Procede pour reduire la sensibilite a l'infection a vih
Trinchieri et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation
CA2087525C (fr) Immunotherapie adoptive au moyen de l'interleukine 7
EP0742795B1 (fr) Anticorps monoclonaux immunostimulants
JP7004761B2 (ja) 癌治療のための改善された細胞組成物および方法
US20040091476A1 (en) Methods of using human receptor protein 4-1BB
US6039684A (en) Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome
Kornbluth The emerging role of CD40 ligand in HIV infection
WO1995020605A9 (fr) Anticorps monoclonaux immunostimulants
WO2018229163A1 (fr) Méthodes d'activation des lymphocytes t v delta 2 négatifs gamma delta
Levitt et al. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
MXPA05007129A (es) Usos de la citocina de mamifero; reactivos relacionados.
US6074635A (en) T cell activation
WO2003038062A2 (fr) Generation et utilisation de cellules tc1 et tc2
Nguyen et al. Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells
Bettens et al. Lymphokine gene expression related to CD4 T cell subset (CD45R/CDw29) phenotype conversion
Yamane et al. Effective stimulation for IL-12 p35 mRNA accumulation and bioactive IL-12 production of antigen-presenting cells interacted with Th cells
US20230355678A1 (en) Methods for improving t cell efficacy
JP6963560B2 (ja) Ｔ細胞の拡張及び活性化の方法
US6319493B1 (en) Treatment of neoplastic disease with interleukin-10
Yoneda et al. Effects of tumour necrosis factor-alpha (TNF-α), IL-1β and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes
WO2000009150A2 (fr) Cytokines et recepteur de cytokines, agoniste, antagoniste et/ou combinaison d'anticorps a usage therapeutique
US6022536A (en) Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
EP0845994A1 (fr) Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued